首页> 美国卫生研究院文献>SAGE Open Medicine >Evolving ethics policy and reimbursement issues of vascularizedcomposite allotransplantation: Symposium summary
【2h】

Evolving ethics policy and reimbursement issues of vascularizedcomposite allotransplantation: Symposium summary

机译:不断发展的道德政策和报销问题复合同种异体移植:研讨会总结

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In this article, we present a report from a national meeting titled, “Evolving Issues of Vascularized Composite Allotransplantation—A Symposium on Ethics, Policy, and Reimbursement Issues,” which convened in September 2017. We discuss the maturation of vascularized composite allotransplantation from an emerging technology to becoming an extension of clinical practice for select patients with complex reconstructive needs. Viewpoints and action items were presented by and discussed among the 70+ clinicians, researchers, policymakers, ethicists, healthcare administrators, and third-party payers who attended the symposium with the goals of implementing a collaborative roadmap for vascularized composite allotransplantation growth, evaluation, and sustainability by establishing a unified plan to help address concerns of the public, policymakers, and healthcare finance. We review the current status of vascularized composite allotransplantation in clinical practice and summarize symposium discussions regarding ethical considerations, reimbursement, payer strategies, and standardization of data collection.
机译:在本文中,我们介绍了一次全国性会议的报告,题为“正在发展中的血管化复合同种异体移植—伦理,政策和补偿问题座谈会”,该会议于2017年9月召开。新兴技术已成为具有复杂重建需求的精选患者的临床实践的扩展。参加专题讨论会的70多名临床医生,研究人员,政策制定者,伦理学家,医疗保健管理者和第三方付款者介绍并讨论了观点和行动项目,目的是实施协作路线图,以实现血管化复合同种异体移植的生长,评估和治疗。通过建立统一的计划来帮助解决公众,决策者和医疗保健融资的可持续性问题。我们在临床实践中回顾了血管化复合同种异体移植的现状,并总结了有关伦理考虑,报销,付款人策略和数据收集标准化的专题讨论会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号